ReviewFrontiers in immunology2026
Therapies for bronchiectasis: mechanisms and potential effects.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bronchiectasis is a complex and heterogeneous disease, and our current understanding of its pathophysiological mechanisms remains in its infancy. Currently, few specifically approved treatments for non-cystic fibrosis bronchiectasis are applied globally, and most guideline-recommended therapies have limited evidence of efficacy. Consequently, the development of new treatment methods is particularly urgent. To gain insight into new drugs under clinical development for adults with bronchiectasis, we conducted a review of the scientific literature and clinical trial registries. In this review, we discuss in detail the mechanisms and potential effects of these emerging therapies, which focus on their anti-inflammatory effects, enhancement of mucociliary clearance, and anti-infectious effects. Clinical research has revealed significant variability among patients, suggesting the need for a multidisciplinary and comprehensive approach. Future efforts should focus on patient stratification using biomarkers and clinical assessments, with an emphasis on precision medicine. Furthermore, it is essential to develop new antibiotics, innovative neutrophil-targeted therapies, and effective mucus-clearing agents to alleviate patient disease burden and minimize the risk of exacerbations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.